Cargando…

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand

BACKGROUND: Hemophilia patients use factor-clotting concentrates (factor VIII for hemophilia A and factor IX for hemophilia B) for improved blood clotting. These products are used to prevent or stop bleeding episodes. However, some hemophilia patients develop inhibitors (i.e., the patient’s immune s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Darshan A., Oladapo, Abiola O., Epstein, Joshua D., Novack, Aaron R., Neufeld, Ellis J., Hay, Joel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397845/ https://www.ncbi.nlm.nih.gov/pubmed/27015254 http://dx.doi.org/10.18553/jmcp.2016.22.2.149

Ejemplares similares

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
por: Butros, Linda, et al.
Publicado: (2011)

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
por: Lentz, Steven R, et al.
Publicado: (2014)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

Use of recombinant factor VIIa in orthotopic liver transplant
por: Bhatia, Pradeep
Publicado: (2011)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment
por: Munawar Ali, Rabeea, et al.
Publicado: (2023)

Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
por: Kissela, Brett M, et al.
Publicado: (2008)

Recombinant factor VIIa in severe trauma: further study needed
por: Galvan, Dan A, et al.
Publicado: (2006)

Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants
por: Dang, Chi N, et al.
Publicado: (2010)

Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient
por: Martin, Jeremiah T., et al.
Publicado: (2009)

The utility of recombinant factor VIIa as a last resort in trauma
por: Mamtani, Rishi, et al.
Publicado: (2012)

Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
por: Yampolsky, Natalie, et al.
Publicado: (2014)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
por: Demartis, Francesco, et al.
Publicado: (2017)

The use of recombinant factor VIIa as a haemostatic agent in ICU patients
por: Vernikos, P, et al.
Publicado: (2004)

Predicting response to recombinant activated factor VIIa administration in the critically ill
por: Pugh, R, et al.
Publicado: (2008)

Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
por: Park, Jeong A
Publicado: (2016)

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
por: VALENTINO, L A, et al.
Publicado: (2012)

Violin concertos in C major, Hob. VIIa:1 ; in G major, Hob. VIIa:4 ; in A major, Hob. VIIa:3 /
por: Haydn, Joseph, 1732-1809
Publicado: (1989)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(®))
por: Viuff, D., et al.
Publicado: (2008)

Evaluation of Recombinant Factor VIIa Treatment for Massive Hemorrhage in Patients with Multiple Traumas
por: Koh, Young Rae, et al.
Publicado: (2012)

Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
por: Mohr, Alicia M, et al.
Publicado: (2005)

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
por: Puetz, John
Publicado: (2010)

Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage
por: Chou, S, et al.
Publicado: (2011)

Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis
por: Yaghi, Shadi, et al.
Publicado: (2015)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium
por: Magon, Navneet, et al.
Publicado: (2012)

Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
por: Grounds, R Michael, et al.
Publicado: (2005)

The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework
por: Lin, Y, et al.
Publicado: (2012)

Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope
por: Qi, Xingshun, et al.
Publicado: (2017)

Emergency cesarean section in glanzmann thrombasthenia: Anaesthetic management without recombinant factor VIIa
por: Priyanka, Andal, et al.
Publicado: (2023)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Correction: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
por: Grounds, R Michael, et al.
Publicado: (2005)

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
por: Tiede, Andreas, et al.
Publicado: (2018)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m5mapfkjqs8s204iu1uf9iabrs